Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(78)
Filter by content year
2024
(2)
2023
(4)
2022
(13)
2021
(27)
2020
(32)
Filter by form group
Filter by category
All
(78)
(-)
Collaborators
(78)
(-)
Science
(78)
Clinical
(47)
Other
(34)
Events
(5)
Filter by category
Search
News
Pfizer und BioNTech geben erfolgreiche erste Zwischenanalyse ihres COVID-19-Impfstoffkandidaten in laufender Phase-3-Studie bekannt
News
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
News
Pfizer und BioNTech schließen Phase-3-Studie erfolgreich ab: Impfstoffkandidat gegen COVID-19 erreicht alle primären Endpunkte
News
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
News
BioNTech and Fosun Pharma Announce the Start of a Phase 2 Clinical Trial of Lead mRNA COVID-19 Vaccine BNT162b2 in China
News
BioNTech und InstaDeep geben strategische Partnerschaft bekannt und gründen AI Innovation Lab zur Entwicklung neuer Immuntherapien
News
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies
News
Pfizer und BioNTech veröffentlichen Ergebnisse der Phase-3-Studie mit COVID-19-Impfstoffkandidat BNT162b2 im The New England Journal of Medicine
News
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
News
Pfizer und BioNTech veröffentlichen neue Daten zur Immunantwort nach Impfung mit COVID-19-Impfstoffkandidat BNT162b2 aus deutscher Phase-1/2-Studie
Pagination
Page 1
Next page
››